Proteomics in neuropsychiatric disorders

International Journal of Neuropsychopharmacology

Volumn 4, Issue 1, 2001, Pages 93-102

  Rohlff, Christian ^a  

^a Oxford GlycoSciences   (United Kingdom)

Author keywords

Brain; Cerebrospinal fluid (CSF); Proteomics; Psychiatric disorders

Indexed keywords

NEUROPEPTIDE; NEUROTRANSMITTER; PROTEOME;

ARTICLE; CELL POPULATION; CELL TYPE; CEREBROSPINAL FLUID EXAMINATION; COMPLEX FORMATION; DATA BASE; DISEASE MARKER; HUMAN; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

BIOLOGICAL MARKERS; BRAIN; GENE EXPRESSION; HUMANS; MENTAL DISORDERS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PROTEINS; PROTEOME;

EID: 0035040631     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145701002267     Document Type: Article

References (80)

1. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia
2. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies
3. Cerebrospinal fluid inositol monophosphatase: Elevated activity in depression and neuroleptic-treated schizophrenia
4. Elevation of immunoreactive CSF TRH in depressed patients
5. The potential use of laser capture microdissection to selectively obtain distinct population of cells for proteome analysis - Preliminary findings
6. Susceptibility loci for bipolar disorder: Overlap with inherited vulnerability to schizophrenia
7. The growth-associated protein GAP-43 is increased in the hippocampus and in the gyrus cinguli in schizophrenia
8. New views on the course and treatment of schizophrenia
9. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro
10. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS
11. + therapy and site of origin on cerebrospinal fluid beta-amyloid precursor protein derivatives
12. β-amyloid precursor protein-like immunoreactivity can be altered in humans by drugs affecting neurotransmitter function
13. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing
14. Cerebrospinal fluid and urinary biogenic amines in depressed patients and healthy controls
15. Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon?
16. Decreased hippocampal (CA3) NMDA receptors in schizophrenia
17. A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals
18. Laser capture microdissection
19. Cerebrospinal fluid glutamate inversely correlates with positive symptom severity in unmedicated male schizophrenic/schizoaffective patients
20. Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia
21. Analysis of proteins from membrane-enriched cerebellar preparations by two-dimensional gel electrophoresis
22. CSF neuroactive steroids in affective disorders: Pregnenolone, progesterone, and DBI
23. CSF neurochemistry in depressed, manic and schizophrenic patients compared with that of normal controls
24. Bipolar illness and schizophrenia as oligogenic diseases: Implications for the future
25. Neurotrophin-3 levels in the cerebrospinal fluid of patients with schizophrenia or medical illness
26. Relations between neuropsychological performance and brain morphological and physiological measures in monozygotic twins discordant for schizophrenia
27. Decreased levels of synaptosomal associated protein 25 on the brain of patients with Down Syndrome and Alzheimer's disease
28. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain
29. Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era
30. Correlation between protein and mRNA abundance in yeast
31. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways
32. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease
33. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease
34. p38 kinase is activated in the Alzheimer's disease brain
35. Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - Inverse correlation with dementia severity
36. Molecular mechanisms underlying mood stabilization in manic-depressive illness: The phenotype challenge
37. Simultaneous analysis of endogenous neurotransmitters and neuropeptides in brain tissue using capillary electrophoresis - Microelectrospray-tandem mass spectrometry
38. Cerebrospinal fluid protein variations in alpha-2 haptoglobin is common to Alzheimer's disease and schizophrenia
39. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder
40. Enrichment of human brains proteins by heparin chromatography
41. 7TM receptors: The splicing on the cake
42. Apolipoprotein E epsilon2 allele and early onset schizophrenia
43. Schizophrenia and bipolar disorder: Findings from studies of the Stanley Foundation Brain Collection
44. Mitogen-activated protein kinases in schizophrenia
45. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia
46. Controlled trials of inositol in psychiatry
47. Cerebrospinal cytokine levels in patients with acute depression
48. Elevated endogenous cannabinoids in schizophrenia
49. Clinical research in the age of neuroscience
50. Gene expression profiles of laser-captured adjacent neuronal subtypes
51. The expression of an N-CAM serum fragment is positively correlated with severity of negative features in type II schizophrenia
52. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: Therapeutic implications
53. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked?
54. Signal transduction abnormalities in Alzheimer's disease: Evidence of a pathogenic stimuli
55. Creatine kinase and aldolase in serum: Abnormalities common to acute psychoses
56. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia
57. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: Relationship to sleep architecture
58. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties
59. Post-translational modification of proteins and the discovery of new medicine
60. Proteomics in molecular medicine
61. Proteomics as an emerging technology in pharmaceutical R & D
62. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation
63. Monozygotic twins discordant for schizophrenia are discordant for N-CAM and L1 in CSF
64. Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients
65. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers
66. Proteomics in molecular medicine - Applications in central nervous system disorders
67. Fingerprinting disease with protein chip arrays
68. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder
69. Differential involvement of small G proteins in Alzheimer's disease
70. Prophylactic estrogen in recurrent postpartum affective disorder
71. Laser-assisted microdissection, applications in molecular pathology
72. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: No alteration of soluble gp130
73. CSF SNAP-25 in schizophrenia and bipolar illness. A pilot study
74. Analysis of blood plasma proteins in patients with Alzheimer's disease by two-dimensional electrophoresis, sequence homology and immunodetection
75. Further studies of elevated cerebrospinal fluid neuronal cell adhesion molecule in schizophrenia
76. CSF N-CAM in neuroleptic-naïve first-episode patients with schizophrenia
77. Enhancing protein solubilization with nondetergent sulfobetaines
78. Cerebrospinal fluid angiotensin-converting enzyme (ACE) correlates with length of illness in schizophrenia
79. Human cerebrospinal fluid protein database (edition 1992)
80. Messenger RNA translation state: The second dimension of high-throughput expression screening